Significant Advances in NSCLC Treatment: Insights from Phase III OptiTROP-Lung06 Study Results

Phase III OptiTROP-Lung06 Study Results Highlight Progress in NSCLC Treatment

The recent oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress revealed groundbreaking results from the Phase III OptiTROP-Lung06 study concerning the innovative drug sacituzumab tirumotecan (sac-TMT).

Conducted by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, the study aimed at evaluating the efficacy of sac-TMT when combined with MSD's pembrolizumab (KEYTRUDA®) in patients suffering from advanced non-squamous non-small cell lung cancer (NSCLC). This patient group specifically included individuals exhibiting programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) <1%, along with those who were negative for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) alterations.

Key Findings from the Study

One of the notable outcomes of this study was the significant improvement in progression-free survival (PFS). When assessed via Blinded Independent Central Review (BICR), the risk of disease progression or mortality in patients taking sac-TMT combined with pembrolizumab decreased by an impressive 51%, with a hazard ratio (HR) of 0.49. The median PFS for this group was 15.0 months, compared to just 5.7 months for those receiving the standard platinum-based doublet chemotherapy.

Moreover, the median duration of response also appeared to be more durable for patients treated with sac-TMT, reported at 13.6 months versus 6.8 months for the comparative group, indicating an HR of 0.47. While overall survival (OS) data demonstrated a favorable trend, the study observed an HR of 0.58 at this interim analysis, although median OS was yet to be reached for either patient group.

Study Structure and Participant Details

The OptiTROP-Lung06 study involved 455 participants who were assigned randomly to receive either sac-TMT in combination with pembrolizumab or the reactive chemotherapy regimen. Designed as a multicenter, open-label study, it set its primary endpoint on PFS that was evaluated through BICR.

These findings are encouraging, particularly as they represent the first Phase III clinical trial investigating an antibody-drug conjugate (ADC) coupled with an immune checkpoint inhibitor hitting its primary endpoint in first-line treatment for PD-L1 negative, EGFR and ALK negative NSCLC patients.

Safety and Tolerability Considerations

When analyzing the safety profile, sac-TMT combined with pembrolizumab exhibited results consistent with known safety data of the individual medications. Notably, it presented lower rates of Grade ≥3 treatment-emergent adverse events (TEAEs) compared to the conventional chemotherapy combination. Lesser incidences of TEAEs requiring dose modifications or leading to discontinuation also marked the effectiveness of this treatment combination.

Broader Implications for NSCLC Treatment

Professor Caicun Zhou from Shanghai East Hospital, who led the presentation, emphasized the clinical importance of these findings. He noted that sac-TMT alongside pembrolizumab could provide significant benefits for patients with actionable genomic alterations. Previous study results presented at ASCO 2026 supported the promising efficacy of this combination, further solidifying its role in treating NSCLC without specified genomic alterations, regardless of PD-L1 status.

Conclusion

As Kelun-Biotech continues forward, sacituzumab tirumotecan stands out not only as a groundbreaking treatment option but also sheds light on a new path for therapies targeting advanced NSCLC. This innovative combination may enhance outcomes for patients who previously faced limited alternatives, reinforcing the ongoing quest for improved cancer therapies and the continued development of novel pharmaceuticals.